26 results
424B3
PYXS
Pyxis Oncology Inc
30 Jun 23
Prospectus supplement
4:05pm
or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other … or disrupt Apexigen’s operations, including Apexigen’s ability to conduct its analyses, deliver test results, process claims and appeals, provide customer
S-4/A
shonogq5ilmpcoqh4bg
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
u94aql6up gqrft8z
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
425
6l559i9gluhvu0r
24 May 23
Business combination disclosure
7:05am
425
d2rt4vajuf
24 May 23
Business combination disclosure
7:03am
8-K
EX-2.1
d4wtj
24 May 23
Pyxis Oncology to Acquire Apexigen
6:59am
10-K
s13bfk2
29 Mar 22
Annual report
7:36am
10-Q
3zmi5tna
15 Nov 21
Quarterly report
7:54am
424B4
f7jb nnv3
8 Oct 21
Prospectus supplement with pricing info
5:00pm
S-1/A
EX-10.14
x85l2v0k723fcei
30 Sep 21
IPO registration (amended)
9:11pm